Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gain Therapeutics Inc
(NQ:
GANX
)
1.360
+0.160 (+13.33%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gain Therapeutics Inc
< Previous
1
2
3
4
5
Next >
Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research
August 29, 2023
Bethesda, MD, August 29, 2023 (PlatoData via 500NewsWire) -- Gain Therapeutics, Inc. (Nasdaq: GANX), a pioneering biotechnology company specializing in innovative allosteric small molecule therapies,...
Via
TheNewswire.com
Gain Therapeutics Presents New Preclinical Data Demonstrating a Reduction of Plasma Neurodegeneration Biomarker NfL after Administration of its Drug Candidate GT-02287 in GBA1 Parkinson’s Disease Model
August 28, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Announces Second Quarter 2023 Financial Results and Business Update
August 10, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Expert Ratings for Gain Therapeutics
June 12, 2023
Via
Benzinga
Chardan Capital Maintains Buy Rating for Gain Therapeutics: Here's What You Need To Know
May 15, 2023
Via
Benzinga
Where Gain Therapeutics Stands With Analysts
May 15, 2023
Via
Benzinga
Analyst Expectations for Gain Therapeutics's Future
May 15, 2023
Via
Benzinga
Gain Therapeutics Announces Acceptance of Late Breaking Abstract for Presentation at the International Congress of Parkinson’s Disease and Movement Disorders®
August 07, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics to Participate in the 2023 BTIG Virtual Biotechnology Conference
July 31, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics to Present at the Jefferies Healthcare Conference
June 01, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Expert Ratings for Gain Therapeutics
December 09, 2022
Via
Benzinga
Analyst Ratings for Gain Therapeutics
December 09, 2022
Via
Benzinga
Gain Therapeutics Touts Additional Encouraging Preclinical Data For Lead Parkinson's Program
September 26, 2022
Via
Benzinga
Gain Therapeutics Reports First Quarter 2023 Financial Results and Business Update
May 12, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Awarded CHF 2.5 million Innosuisse Grant to Advance Lead Program in GBA1 Parkinson’s Disease
May 03, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Appoints C. Evan Ballantyne as Chief Financial Officer
April 12, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics to Present Positive Preclinical Data on its GBA1 Program at the AD/PD 2023 Meeting
March 29, 2023
Study results support the disease-modifying potential of structurally targeted allosteric regulators of GCase for the treatment of Alzheimer’s disease
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Reports Full Year 2022 Financial Results and Business Update
March 23, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics to Participate in Virtual Fireside Chat On Computational Biology in Drug Discovery with Key Opinion Leaders
March 22, 2023
Panel, moderated by Hartaj Singh of Oppenheimer & Co., will be held on Wednesday, March 29, 2023 at 12:00 pm ET
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Announces Grant Award by Eurostars with Innosuisse for Alpha-1 Antitrypsin Deficiency Research Program
March 21, 2023
Grant awarded to consortium led by Gain Therapeutics to advance the development of proprietary allosteric small molecule regulators against Alpha-1 Antitrypsin (AAT) Deficiency
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics to Participate in the Oppenheimer 33rd Annual Healthcare Conference
March 09, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Presents New Preclinical Data from its Gaucher Disease Program at the 19th Annual WORLDSymposium
February 27, 2023
Study results support the disease-modifying potential of GCase-targeting small molecule therapy for neuronopathic Gaucher disease
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics to Participate in Upcoming Scientific and Medical Conferences
February 02, 2023
Gain to present new preclinical data on its lead programs in GBA1-related diseases
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics to Present at Sidoti Small-Cap Virtual Investor Conference
January 12, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Medtronic To $85? Plus Oppenheimer Slashes PT On This Stock By 67%
November 25, 2022
Via
Benzinga
Heska To $165? Plus BTIG Cuts PT On This Stock By 67%
November 14, 2022
BTIG cut the price target on Gain Therapeutics, Inc. (NASDAQ: GANX) from $30 to $10. BTIG analyst Thomas Shrader maintained a Buy rating on the stock. Gain Therapeutics shares rose 1.3% to close at...
Via
Benzinga
AMD To Rally Around 39%? Here Are 5 Other Price Target Changes For Monday
November 14, 2022
Baird raised Advanced Micro Devices, Inc. (NASDAQ: AMD) price target from $65 to $100. . Baird analyst Tristan Gerra upgraded the stock from Neutral to Outperform. AMD shares rose 5.7% to close at...
Via
Benzinga
Gain Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Business Update
November 10, 2022
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 19, 2022
August 19, 2022
Upgrades
Via
Benzinga
Apple To $185? Here Are 5 Other Price Target Changes For Friday
August 19, 2022
Keybanc raised the price target on Apple Inc. (NASDAQ: AAPL) from $177 to $185. However, Keybanc analyst Brandon Nispel maintained the stock with an Overweight. Apple shares fell 0.9% to $172.63 in...
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.